Evonik has manufactured the first batch of GMP-quality pharmaceutical lipids at its new Lipid Innovation Center in Lafayette, Indiana. The large-scale facility at Evonik's Tippecanoe site is supported by the U.S. government and will produce pharmaceutical lipids that enable the manufacture of advanced therapies in the U.S. Full capacity is scheduled to come on stream by mid-2027.
The first product from the new center is PhytoChol, a non-animal-derived cholesterol and essential excipient for lipid nanoparticles. The facility is a flexible production center designed to support multiple lipid chemistries, manufacturing processes and products. Therapies enabled by these lipids are used in areas such as cancer immunotherapy, gene therapy and vaccine platforms supporting preparedness for future infectious disease outbreaks.
Lipids are essential for encapsulating and delivering nucleic acid-based drugs such as mRNA. Proven in COVID-19 vaccines, LNPs have become a leading delivery system, with the LNP market estimated to reach $2.7 billion by 2034.
Guido Skudlarek, head of Evonik's Health Care business line, said LINC is about ensuring that the next generation of RNA medicines can be developed and manufactured reliably, at scale and within the U.S.
The center is part of an integrated global network combining expertise in lipid chemistry, LNP formulation, process engineering, sterile manufacturing and regulatory affairs. Evonik Vancouver Laboratories develops LNP formulations and supports clinical manufacturing, with a new GMP facility announced in August. Late-stage clinical and commercial processes transfer to Birmingham, Alabama. Sites in Dossenheim and Hanau, Germany, and Tippecanoe supply lipids and adjuvants, while the Cambridge Innovation Satellite in Greater Boston adds R&D capabilities.